Reduced immunogenic potential of membrane filtered bovine thrombin preparations for hemostatic application

Clinical and Applied Thrombosis/Hemostasis

Volumn 15, Issue 1, 2009, Pages 32-40

  Zhu, He ^a   Hoppensteadt, Debra ^a   Wahi, Rakesh ^a   Cunanan, Josephine ^a   Adiguzel, Cafer ^a   Bick, Rodger L ^a   Fareed, Jawed ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Bovine thrombin; Factor Va; Immunoglobulin G; Topical hemostatic agents; Western blot

Indexed keywords

ANTISERUM; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 5A; IMMUNOGLOBULIN G; PROTEIN G; THROMBIN 4A; THROMBIN 4B; THROMBIN DERIVATIVE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; COW; DRUG CONTAMINATION; DRUG PURIFICATION; HEMOSTASIS; IMMUNOGENICITY; MEMBRANE FILTER; NONHUMAN; PRIORITY JOURNAL; RABBIT;

ANIMALS; BLOTTING, WESTERN; CATTLE; ELECTROPHORESIS, GEL, TWO-DIMENSIONAL; FILTRATION; HEMOSTASIS; HEMOSTASIS, SURGICAL; HEMOSTATICS; IMMUNOGLOBULIN G; RABBITS; THROMBIN;

EID: 58449106270     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029608322550     Document Type: Article

References (21)

1. Lawson JH The clinical use and immunologic impact of thrombin in surgery. Semin Thromb Hemost. 2006 ; 32 (suppl 1). 98-110.
2. Alvin BM, Weinstein MJ, Finlayson JS, et al. Fibrin sealant: summary of a conference on characteristics and clinical use. Transfusion. 1995 ; 35: 783-790.
3. Ortel TL, Mercer MC, Thames EH, et al. Immunologic impact and clinical outcomes after surgical exposure to bovine thrombin. Ann Surg. 2001 ; 233: 88-96.
4. Dorion RP, Hamati HF, Landis B., et al. Risk and clinical significance of developing antibodies induced by topical thrombin preparations. Arch Pathol Lab Med. 1998 ; 122: 887-894.
5. Schoenecker JG, Hauck RK, Mercer MC, et al. Exposure to topical bovine thrombin during surgery elicits a response against the xenogenic carbohydrate galactose(alpha1-3)galactose. J Clin Immunol. 2000 ; 20: 434-444.
6. Jackson MR, MacPhee MJ, Drohan WN, et al. Fibrin sealant: current and potential clinical applications. Blood Coagul Fibrinolysis. 1996 ; 7: 737-746.
7. Spotnitz W. Fibrin sealant in the United States: clinical use at the University of Virginia. Semin Thomb Hemost. 1995 ; 74: 482-485.
8. Nelson PA, Powers JN, Estridge TD, et al. Serological analysis of patients treated with a new surgical hemostat containing bovine proteins and autologous plasma. J Biomed Mater Res. 2001 ; 58: 710-719.
9. Ortel TL, Charles LA, Keller FG, et al. Topical thrombin and acquired coagulation factor inhibitors: clinical spectrum and laboratory diagnosis. Am J Hematol. 1994 ; 45: 128-135.
10. Rapaport SI, Zivelin A., Minow RA, et al. Clinical significance of antibodies to bovine and human thrombin and factor V after surgical use of bovine thrombin. Am J Clin Pathol. 1992 ; 97: 84-91.
11. Cmolik BL, Spero JA, Magovern GJ, et al. Redo cardiac surgery: late bleeding complications from topical thrombin-induced factor V deficiency. J Thorac Cardiovasc Surg. 1993 ; 105: 222-228.
12. Chouhan VD, De la cadena RA, Nagaswami C., et al. Simultaneous occurrence of human antibodies directed against fibrinogen, thrombin, and factor V after exposure to bovine thrombin: effects on blood coagulation, protein C activation and platelet function. Thromb Haemost. 1997 ; 77: 343-349.
13. Zehnder JL, Leung LLK. Development of antibodies to thrombin and factor V with recurrent bleeding in a patient exposed to topical bovine thrombin. Blood. 1990 ; 76: 2011-2016.
14. Streiff MB, Ness PM Acquired FV inhibitors: a needless iatrogenic complication of bovine thrombin exposure. Transfusion. 2002 ; 42: 18-26.
15. Chapman WC, Singla N., Genyk Y., et al. A phase 3, randomized, double-blind comparative study of the efficacy and safety of topical recombinant human thrombin and bovine thrombin in surgical hemostasis. J Am Coll Surg. 2007 ; 205: 256-265.
16. Banninger H., Hardegger T., Tobler A., et al. Fibrin glue in surgery: frequent development of inhibitors of bovine thrombin and human factor V. Br J Hematol. 1993 ; 85: 528-532.
17. Knobl P., Lechner K. Acquired factor V inhibitors. Baillieres Clin Hematol. 1998 ; 11: 305-318.
18. Tadokoro K., Ohtoshi T., Takafuji S., et al. Topical thrombin-induced IgE-mediated anaphylaxis. RAST analysis and skin test studies. J Allergy Clin Immunol. 1991 ; 88: 620-629.
19. Suzuki K., Dahlback B., Stenflo J. Thrombin-catalyzed activation of human coagulation factor V. J Biol Chem. 1982 ; 257: 6556-6564.
20. Terrab A., Pawlak D., Spaay P., et al. Further removal of factor V related antigen from bovine thrombin by utilizing a membrane-filtration step. ClinAppl Thromb Hemost. 2008 ; 14: 135-140.
21. Lowry OH, Rosebrough NJ, Farr AL, et al. Protein measurement with the folin phenol reagent. J Biol Chem 1951 ; 193: 265-275.